Hannover Medical School spinout Cardior has welcomed both new and existing backers, such as Bristol Myers Squibb, for a series B round led by Inkef Capital.

Cardior Pharmaceuticals, a Germany-based developer of therapeutics for cardiac diseases based on research at Hannover Medical School, closed a €64m ($76m) series B round today led by venture capital firm Inkef Capital. Pharmaceutical firm Bristol Myers Squibb (BMS) took part in the round together with Fund+, Sunstone, Hadean Ventures, Coparion, LSP, BioMedPartners and High-Tech Gründerfonds…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.